A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

This study is testing whether combining gilteritinib (which targets an FLT3 mutation) with either ivosidenib (which targets an IDH1 mutation) or enasidenib (which targets an IDH2 mutation) can help people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic mutations. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML that has relapsed (come back) or is refractory (not responding to treatment) - Your AML has a relevant genetic mutation (FLT3, IDH1, or IDH2) that makes you potentially eligible for one of these targeted drugs - You are willing to follow the study visit schedule **You may NOT be eligible if...** - Your AML does not have the genetic mutations targeted by these drugs - Your cancer has not been previously treated - Your overall health does not meet the required criteria Talk to your doctor to see if this trial is right for you.